Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Feb 17, 2022 6:26pm
573 Views
Post# 34439984

RE:RE:RE:Commercialization Timeline Change

RE:RE:RE:Commercialization Timeline Change
gebremeskel wrote: Maybe leaving out mention of a partnership was an oversight, but how could we be granted accelerated approval by January 2023? Could there have been a communication from the FDA we haven't heard about yet?

enriquesuave wrote:

No partnership,so maybe a Buyout instead?  Who knows, or just an oversight?

 

Eoganacht wrote: In the Sep 2021 Corporate Presentation, on the Phase II Timeline page, commercialization is set to begin in mid-2025 and there is a note - Partner with Big Pharma To Commercialize.

In the Feb 7 2022 Corporate Presentation, on the Phase II Timeline page, commercialization is set to begin in January 2023 (11 months from now) and there is no mention of partnering with big pharma.

What has changed in the last 5 months?

 

 




 

Thanks Eoganacht...I think the latest presentation timeline simply better represents TLT's stance.  Their latest projected commercialization timeline is Jan 2023 to Dec 2025.  Jan 2023 is oddly fast...even a Big Pharma partner or buyout wouldn't expedite this trial to that degree imo.  To me, it may simply mean FDA guidance could be allowing earlier commercialization based on fewer patients treated...so long as the data supports it.  Otherwise, the trial would simply be extended (needing 100+ patients) in order to prove its worth to the FDA  = projected Dec 2025 timeline.  JMO.

<< Previous
Bullboard Posts
Next >>